JP2020536048A - 発毛を調節するための組成物及び方法 - Google Patents

発毛を調節するための組成物及び方法 Download PDF

Info

Publication number
JP2020536048A
JP2020536048A JP2020512367A JP2020512367A JP2020536048A JP 2020536048 A JP2020536048 A JP 2020536048A JP 2020512367 A JP2020512367 A JP 2020512367A JP 2020512367 A JP2020512367 A JP 2020512367A JP 2020536048 A JP2020536048 A JP 2020536048A
Authority
JP
Japan
Prior art keywords
acid
pharmaceutical composition
electron transport
transport chain
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020512367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536048A5 (enExample
Inventor
ロウリー，ウィリアム，イー．
クリストフ，ヘザー，アール．
ミランダ，マチルド
フローレス，エイミー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2020536048A publication Critical patent/JP2020536048A/ja
Publication of JP2020536048A5 publication Critical patent/JP2020536048A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)
JP2020512367A 2017-09-29 2018-09-28 発毛を調節するための組成物及び方法 Withdrawn JP2020536048A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566031P 2017-09-29 2017-09-29
US62/566,031 2017-09-29
PCT/US2018/053351 WO2019067860A1 (en) 2017-09-29 2018-09-28 COMPOSITIONS AND METHODS FOR MODULATION OF HAIR GROWTH

Publications (2)

Publication Number Publication Date
JP2020536048A true JP2020536048A (ja) 2020-12-10
JP2020536048A5 JP2020536048A5 (enExample) 2021-11-18

Family

ID=65903207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020512367A Withdrawn JP2020536048A (ja) 2017-09-29 2018-09-28 発毛を調節するための組成物及び方法

Country Status (16)

Country Link
US (1) US20200253917A1 (enExample)
EP (1) EP3687528A4 (enExample)
JP (1) JP2020536048A (enExample)
KR (1) KR20200062242A (enExample)
CN (1) CN111295188A (enExample)
AU (1) AU2018339064A1 (enExample)
BR (1) BR112020003349A2 (enExample)
CA (1) CA3077359A1 (enExample)
CL (1) CL2020000676A1 (enExample)
EA (1) EA202090855A1 (enExample)
IL (1) IL272827A (enExample)
MX (1) MX2020002389A (enExample)
PE (1) PE20210464A1 (enExample)
PH (1) PH12020500300A1 (enExample)
SG (2) SG10202109849SA (enExample)
WO (1) WO2019067860A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019015552A2 (pt) 2017-02-24 2020-03-17 The Regents Of The University Of California Composições e métodos para promover crescimento capilar com os inibidores de mpc1
MX2019015475A (es) 2017-06-30 2020-02-19 Univ California Composiciones y metodos para modular el crecimiento del cabello.
KR102561912B1 (ko) * 2021-04-09 2023-07-31 차의과학대학교 산학협력단 세팔로틴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 탈모방지 또는 발모촉진용 조성물
CN113694063A (zh) * 2021-08-31 2021-11-26 佛山市第一人民医院（中山大学附属佛山医院） 一种组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014221D0 (en) * 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
AU3982601A (en) * 2000-02-23 2001-09-03 Orentreich Foundation For The Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
EP1796660B1 (en) * 2004-09-17 2016-11-23 BioMAS Ltd. Use of ammonium trichloro(dioxyethylene-o,o')tellurate (as101) for the inhibition of interleukin-1beta-converting enzyme
AU2006339311A1 (en) * 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8343962B2 (en) * 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
US9308181B2 (en) * 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US8563500B2 (en) * 2007-09-05 2013-10-22 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Methods and compounds for treating diseases caused by reactive oxygen species
EP3178465A1 (en) * 2010-12-06 2017-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
CN106880693A (zh) * 2017-03-22 2017-06-23 广州国草夏方生物科技有限公司 一种治疗脂溢性脱发的生发液组合物及其制备方法

Also Published As

Publication number Publication date
CN111295188A (zh) 2020-06-16
AU2018339064A1 (en) 2020-02-27
PE20210464A1 (es) 2021-03-08
EP3687528A4 (en) 2021-07-21
SG11202001516QA (en) 2020-03-30
IL272827A (en) 2020-04-30
SG10202109849SA (en) 2021-10-28
CL2020000676A1 (es) 2020-09-25
US20200253917A1 (en) 2020-08-13
EA202090855A1 (ru) 2020-06-26
PH12020500300A1 (en) 2020-11-09
WO2019067860A1 (en) 2019-04-04
EP3687528A1 (en) 2020-08-05
KR20200062242A (ko) 2020-06-03
BR112020003349A2 (pt) 2020-08-18
MX2020002389A (es) 2020-10-01
CA3077359A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
JP6865193B2 (ja) 寿命を拡大させ、かつ加齢関連疾患の発症を遅らせるための方法
JP2021152032A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2020536048A (ja) 発毛を調節するための組成物及び方法
JP6796097B2 (ja) 食欲不振制御化合物の組成物および使用方法
CN101426490B (zh) 包含α-酮戊二酸/盐的组合物及其用于调节肌肉性能的用途
JP2011126886A (ja) サフィンゴールの医薬組成物およびその使用方法
JP2019034953A (ja) 体重増加用化合物の長期使用のための組成物と方法
US10024846B2 (en) Methods for treating diet-induced obesity by decreasing or inhibiting P2Y2 purinergic receptor expression or activity
US11576875B2 (en) Composition comprising ethyl vanillin as effective ingredient for exhibiting effect of muscle strengthening, muscle enhancement, muscle differentiation, muscle regeneration, or sarcopenia suppression
BR112015001989B1 (pt) Uso de butilidenoftalida (bp)
EP3366288B1 (en) Lithium ascorbate exhibiting anti-stress, anxiolytic and anti-depression activity
US20210128596A1 (en) Compositions and methods for treating septic cardiomyopathy
HK40026046A (en) Compositions and methods for modulating hair growth
US20230040125A1 (en) Targeting the intrinsic apoptotic machinery in glioblastoma
WO2025166338A2 (en) Systemic mpc inhibition to reverse signs of aging
CN119698284A (zh) 用于治疗X-ALD的甲状腺β激动剂给药方案
JP7478894B1 (ja) 痒みの予防又は改善剤
RU2718748C1 (ru) Способ коррекции метаболизма при риске развития жирового гепатоза у лактирующих коров
WO2023239842A1 (en) Beta carbolines as topical anti-inflammatory agents for application to mucous membranes
JP2024079050A (ja) 痒みの予防又は改善剤
JP2024079052A (ja) 痒みの予防又は改善剤
JP2020117489A (ja) 脳癌の治療方法
RU2557889C1 (ru) Средство для лечения кокцидиозов у птиц и животных
HK40089668A (zh) 含有nr及/或nmn与芝麻素类的组合物
HK40089161A (zh) 烟醯胺腺嘌呤二核苷酸(nad)浓度上升剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200326

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20201216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211007

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220621